A phase i study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer

Gastric Cancer

Volumn 17, Issue 1, 2014, Pages 161-172

  Yamada, Yasuhide ^a   Kiyota, Naomi ^b   Fuse, Nozomu ^c   Kato, Ken ^a   Minami, Hironobu ^b   Hashizume, Kensei ^d   Kuroki, Yoshihiro ^d   Ito, Yuichiro ^d   Ohtsu, Atsushi ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c National Cancer Center   (Japan)

^d BAYER YAKUHIN LTD   (Japan)

Author keywords

Cisplatin; Gastric adenocarcinoma; Phase I; S 1; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOOT DISEASE; HAND DISEASE; HAND FOOT SKIN REACTION; HICCUP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MIDDLE AGED; MONOTHERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIODONTAL DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEINURIA; SKIN EXFOLIATION; SKIN MANIFESTATION; STOMACH CANCER; STOMACH PERFORATION; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; OXONIC ACID; PATIENT COMPLIANCE; PHENYLUREA COMPOUNDS; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84891628705     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0247-9     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
3. Jin M, Lu H, Li J, et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (patients) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol 2008;26:15s(supple;abstr4533)
4. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
5. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
6. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-84.
7. Boku N, Ohtsu A, Nagashima F, Shirao K, Koizumi W. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. Jpn J Clin Oncol. 2007;37:509-14.
8. Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69-79.
9. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947-51.
10. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53.
11. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U. Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit. 1999;21:631-7.
12. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
13. Boyle EI, Weng S, Gollub J, et al. GO: TermFinder - open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. Bioinformatics (Oxford, England). 2004;20:3710-5.
14. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30:306-15.
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
16. Yamada Y, Hamaguchi T, Goto M, et al. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer. 2003;89:816-20.
17. Choi JH, Oh JY, Ryu SK, et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer (Phila). 1997;79:1879-83.
18. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, Altevogt P. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem. 2008;103:1783-97.
19. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010;16:3378-89.